Related Experiment Videos
Bleeding complications following invasive cardiac studies in anticoagulated patients with artificial heart valves
Insights
Patients on anticoagulant therapy undergoing cardiac procedures experienced similar bleeding risks compared to controls. Continuing anticoagulation is deemed safe for artificial heart valve patients needing cardiac investigations.
Area of Science:
- Cardiology
- Vascular Medicine
- Interventional Cardiology
Background:
- Cardiac catheterization and angiography are common invasive procedures.
- Patients with artificial heart valves often require anticoagulation therapy.
- Assessing bleeding risk in anticoagulated patients is crucial.
Purpose of the Study:
- To compare bleeding complications after cardiac catheterization and angiography.
- To evaluate the safety of continuing anticoagulation in specific patient groups.
Main Methods:
- Prospective study comparing two groups of 50 patients each.
- One group received anticoagulation, the control group did not.
- Bleeding complications following cardiac catheterization and angiography were recorded and analyzed.
Main Results:
- Six bleeding complications occurred in the anticoagulated group.
- Five bleeding complications occurred in the control group.
- Complications were slightly more severe in the anticoagulated group, but not significantly.
Conclusions:
- Continuing anticoagulant treatment in patients with artificial heart valves is generally safe.
- The risk of bleeding complications does not necessitate altering current policies for these patients undergoing cardiac investigations.
Abstract:
The number and nature of bleeding complications subsequent to cardiac catheterization and angiography were determined in 50 anticoagulated and 50 control patients. There were six bleeding complications in the anticoagulated group and five in the control group. Although the complications were somewhat more severe in anticoagulated patients, the difference was not enough to justify a change in our general policy of continuing anticoagulant treatment in patients with artificial heart valves who are admitted for postoperative invasive cardiac investigations.